Incannex Healthcare (ASX: IHL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Incannex Healthcare Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Incannex Healthcare (ASX: IHL)
    Latest News

    A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
    Cannabis Shares

    Could ASX cannabis shares be set for a resurgence?

    The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

    Read more »

    Researchers working with medical cannabis.
    Healthcare Shares

    Incannex share price races higher on 'pivotal' trial approval

    This cannabis share is lighting up the market on Thursday.

    Read more »

    a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
    Share Fallers

    Why Incannex, Magellan, Nexted, and Strandline shares are dropping today

    These ASX shares are having a tough start to the week.

    Read more »

    Man sitting in a plane seat works on his laptop.
    Healthcare Shares

    Why you soon won't be able to find Incannex shares on the ASX

    This healthcare share plans to pack its bags and move to the US.

    Read more »

    two men in formal business clothing closely inspect a bud from a cannabis crop.
    Cannabis Shares

    Why ASX cannabis shares just jumped back into the spotlight

    ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

    Read more »

    A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
    Cannabis Shares

    Should I buy Incannex shares while they're at multi-year lows, or steer clear?

    Is the cannabis-based pharma company a bargain buy right now?

    Read more »

    Man in the green house growing medical cannabis
    Cannabis Shares

    A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

    This medicinal cannabis company has been a rare winner in its field.

    Read more »

    Man pointing at a blue rising share price graph.
    Share Gainers

    2 ASX All Ordinaries stocks leaping higher following strong quarters

    Let's dive into why these All Ords shares are besting the index on Thursday.

    Read more »

    A cool white-bearded man holds his hand up signalling you should halt.
    Healthcare Shares

    ASX 300 cannabis stock Incannex suspended ahead of 'material update'

    The Incannex share price is frozen at 14 cents for now.

    Read more »

    An older farmer wearing a checkered shirt and a straw hat stands in a green field of cannabis plants growing up to waist level as he smiles while thinking about the outlook for ASX cannabis shares in FY23
    Cannabis Shares

    Buying ASX cannabis stocks? Here's what the Victorian government is considering right now

    Victoria became the first state to legalise medicinal cannabis in 2016. Now the government is playing catch-up with other laws.

    Read more »

    A graphic showing a rising share price in medical cannabis shares
    Cannabis Shares

    Why did this ASX 300 cannabis share just rocket 12%?

    Incannex is going to make its own pharmaceutical-grade psilocybin drug for clinical trials and potential commercial use.

    Read more »

    A young female ASX investor sits at her desk with her fists raised in excitement as she reads about rising ASX share prices on her laptop.
    Share Gainers

    2 ASX All Ords shares going gangbusters on Monday

    The All Ords are making their shareholders smile on Monday...

    Read more »

    Frequently Asked Questions

    Incannex listed on the ASX in May 2007.

    No, Incannex has not yet paid out any dividends.

    IHL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Incannex Healthcare

    Incannex Healthcare Ltd (ASX: IHL) is a developer of cannabinoid and psychedelic compound medicines. It is currently involved in clinical programs for the treatment of six conditions: Obstructive Sleep Apnea (OSA), Generalised Anxiety Disorder (GAD), traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions.

    The company has an Australian license to import, export, and distribute medicinal cannabis products and has a line of cannabinoid products.

    The Incannex share price hit an all-time high of $5.36 a couple of months after listing in May 2007 before plunging to its current levels.

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    31 Oct 2023 Peter Widdows Buy 230,954 $15,296
    On-market trade. As per announcement on 07-11-2023
    31 Oct 2023 Peter Widdows Buy 280,000 $18,545
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Troy Robert Valentine Non-Executive ChairmanNon-Executive Director Dec 2017
    Troy Valentine has been Chairman of the Board of Directors since December 2017. Mr. Valentine is a finance professional with managerial and Board experience spanning over 27 years. He commenced his career with Australian brokerage firm Hartley Poynton (now Euroz Hartley s Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000 and subsequently became an Associate Director. During his time at Patersons, he was responsible for managing both retail and institutional accounts. Mr. Valentine has significant corporate and capital raising experience, especially with start-ups and small to mid-cap size companies. He is currently a director of Australian boutique corporate advisory firm Alignment Capital Pty Ltd, which he co-founded in 2014.
    Mr Peter Widdows Non-Executive Director Mar 2018
    Mr Valentine has been Chairman of the Board of Directors since December 2017. Mr. Valentine is a finance professional with managerial and Board experience spanning over 27 years. He commenced his career with Australian brokerage firm Hartley Poynton (now Euroz Hartleys Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000 and subsequently became an Associate Director. During his time at Patersons, he was responsible for managing both retail and institutional accounts. Mr. Valentine has significant corporate and capital raising experience, especially with start-ups and small to mid-cap size companies. He is currently a director of Australian boutique corporate advisory firm Alignment Capital Pty Ltd, which he co-founded in 2014.
    Mr Joel Bradley Latham Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
    Joel Latham is the CEO and Managing Director of Incannex Healthcare and is responsible for the Companys commercial operations, strategic decision- making, and oversight of all clinical development assets. Joel has over 15 years commercial management and executive experience, working for a range multi-national publicly traded companies.
    Dr George Anastassov Non-Executive Director Jun 2022
    Dr Anastassov is responsible for APIRx commercial operations, strategic decision-making, and oversight of all clinical development assets. He is one of the developers of the first-in-the world cannabinoid-containing chewing gum-based delivery system among a number of other systems and formulations. Previously, he was CEO and co-founder of AXIM Biotechnologies, which achieved an all-time-high market capitalization of approximately US$1.2B.
    Mr Lekhram Changoer Non-Executive Director Jun 2022
    --
    Mr Robert Bruce Clark Non-Executive Director Aug 2022
    Mr Clark is a senior-level strategic regulatory affairs expert with over 38 years of US and Global regulatory experience, including >20 years with Pfizer Inc. and >10 years with Novo Nordisk A/S. He is an internationally recognized expert on US Food and Drug Administration ('FDA') and the European Medicines Agency (EMA) liaison interactions, US pharmaceutical advertising practices and regulatory aspects related to healthcare professionals and sales force activities. Mr Clark is Vice President, US Regulatory Affairsfor Novo Nordisk where he provides strategic leadership to a team of over 50 regulatory staff and scientists in the development of new medicines. He advises the global executive team on matters related to drug development programs, FDA liaison strategies, managing FDA-related compliance issues, and monitoring emerging US regulatory trends and opportunities.
    Mr Madhukar (Madhu) Bhalla Company Secretary Jul 2021
    -
    Madhukar (Madhu) Bhalla Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 82,707,741 5.23%
    George Anastassov 66,972,077 4.23%
    Prasch Bv 63,954,841 4.04%
    Dr Sudhanshu Agarwal 34,080,364 2.15%
    Cannvalate Pty Ltd 32,000,000 2.02%
    Mr Raymond Laurence Carroll 30,250,000 1.91%
    J P Morgan Nominees Australia Pty Limited 23,906,440 1.51%
    Brownarrows Pty Ltd <Ejm A/C> 23,610,000 1.49%
    BNP Paribas Noms Pty Ltd Deutsche Bank Tca <Drp> 22,880,950 1.45%
    Citicorp Nominees Pty Limited 19,087,124 1.21%
    Mr Peter Widdows 15,973,694 1.01%
    Mr Kaide Wang 15,700,000 0.99%
    IMI LLC 14,642,234 0.93%
    Bagbo Pty Ltd 14,516,434 0.92%
    Mr Brian Peter Byass 14,247,191 0.90%
    Mr Joel Bradley Latham 13,829,129 0.87%
    Gemini Capitall Llc <The Ars A/C> 13,787,086 0.87%
    Slade Technologies Pty Ltd <Embrey Family S/F A/C> 13,350,000 0.84%
    Alignment Capital Pty Ltd 13,194,248 0.83%
    Ryba Llc 13,090,170 0.83%

    Profile

    since

    Note